{"commentary":{"count":8,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":3,"x_thread":3,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05096390\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PAXIPEM","nct_id":"NCT05096390","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=paxipem-nct05096390. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"PAXIPEM","arms":[{"description":"Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.\n\nPembrolizumab will be administrated intravenously (IV) over 30 minutes at the dose of 200 mg every 3 weeks according to recent summary of product characteristics (SPC) together with axitinib.","label":"axitinib + pembrolizumab","type":"EXPERIMENTAL"},{"description":"Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.","label":"axitinib alone (control)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-06","type":"ESTIMATED"},"conditions":["Papillary Renal Cell Carcinoma Type 2"],"enrollment":{"count":72,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Axitinib Oral Tablet [Inlyta]","type":"DRUG"},{"name":"Pembrolizumab Injection [Keytruda]","type":"DRUG"}],"last_update":"2024-01-25","lead_sponsor":"Centre Leon Berard","official_title":"Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.","timeFrame":"At 6 months for each patient"}],"references":[],"start_date":{"date":"2022-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","url":"https://clinicaltrials.gov/study/NCT05096390"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/paxipem-nct05096390"}